Patents by Inventor Pingyu Zhong

Pingyu Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210155685
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
  • Publication number: 20210155686
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
  • Patent number: 10919962
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 16, 2021
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Rosa Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
  • Publication number: 20210024627
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
  • Publication number: 20190144535
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-l Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
  • Patent number: 10167335
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 1, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
  • Patent number: 8957194
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: February 17, 2015
    Assignee: Merck Sharpe & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Publication number: 20150037248
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: February 13, 2013
    Publication date: February 5, 2015
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar, Florent Ginhoux, Pingyu Zhong
  • Patent number: 8877900
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 4, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
  • Patent number: 8802827
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
  • Publication number: 20140220027
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Publication number: 20140121123
    Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.
    Type: Application
    Filed: October 24, 2011
    Publication date: May 1, 2014
    Inventors: Kevin Caili Wang, Yan Li, Mark Hsieh, Xinwei Wang, Xinwei Wang, Feng Dong, Peizhi (Peter) Luo, Pingyu Zhong
  • Patent number: 8697070
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 15, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Patent number: 8637435
    Abstract: The present invention provides expression vectors and helper display vectors which can be used in various combinations as vector sets for display of polypeptides on the outer surface of eukaryotic host cells. The expression vector of the invention can be used alone for soluble expression without having to change or reengineer the display vectors. The display systems of the invention are particularly useful for displaying a genetically diverse repertoire or library of polypeptides on the surface of yeast cells, and mammalian cells.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: January 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin Caili Wang, Peter Peizhi Luo, Pingyu Zhong, Jian Wang
  • Publication number: 20130071379
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: May 8, 2012
    Publication date: March 21, 2013
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Publication number: 20120329679
    Abstract: The present invention provides expression vectors and helper display vectors which can be used in various combinations as vector sets for display of polypeptides on the outer surface of eukaryotic host cells. The expression vector of the invention can be used alone for soluble expression without having to change or reengineer the display vectors. The display systems of the invention are particularly useful for displaying a genetically diverse repertoire or library of polypeptides on the surface of yeast cells, and mammalian cells.
    Type: Application
    Filed: March 23, 2012
    Publication date: December 27, 2012
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kevin Caili Wang, Peter Peizhi Luo, Pingyu Zhong, Jian Wang
  • Publication number: 20120301461
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 29, 2012
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
  • Publication number: 20120231005
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 13, 2012
    Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
  • Publication number: 20120213794
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 23, 2012
    Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
  • Patent number: 8188234
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: May 29, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li